Laura W. Cheever
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura W. Cheever has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Stacy M. Cohen
HIV/AIDS Bureau, Health Resources and Services Administration, Rockville, Maryland, United States of America
4 shared publications Adan Cajina
Affiliation United States Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau, Rockville, Maryland, United States of America
3 shared publications- Antigone Dempsey
U.S. Department of Health and Human Services, Rockville, MD, USA
3 shared publications Latham Avery
Affiliation United States Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau, Rockville, Maryland, United States of America
2 shared publications- Pamela W. Klein
HIV/AIDS Bureau, Health Resources and Services Administration, Rockville, Maryland, United States of America
2 shared publications Allahna Esber
HIV/AIDS Bureau, Health Resources and Services Administration, US Department of Health and Human Services, Rockville, Maryland
1 shared publication
Latest Publications
- 25 April 2023
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 34 (3) , 280-291
Coordinating Care for People With HIV Who Have Lower Incomes and Alternative Sources of Health Care Coverage
As people with HIV increasingly access affordable health care coverage—enabling them to obtain medical care from private providers—understanding how they use the Ryan White HIV/AIDS Program (RWHAP), and their unmet health care needs, can enhance their overall care. We analyzed RWHAP client-level data and interviewed staff and clients at 29 provider organizations to identify trends in health care coverage and service use for clients who received medical care from private providers. The RWHAP helps cover the cost of premiums and copays for these clients and provides medical and support services that help them stay engaged in care and virally suppressed. The RWHAP plays an important role in HIV care and treatment for clients with health care coverage. The growing number of people who receive a combination of services from RWHAP providers and private providers offers opportunities for greater care coordination through communication and data sharing between these settings.
- 25 April 2023
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 34 (3) , 280-291
Coordinating Care for People With HIV Who Have Lower Incomes and Alternative Sources of Health Care Coverage
As people with HIV increasingly access affordable health care coverage—enabling them to obtain medical care from private providers—understanding how they use the Ryan White HIV/AIDS Program (RWHAP), and their unmet health care needs, can enhance their overall care. We analyzed RWHAP client-level data and interviewed staff and clients at 29 provider organizations to identify trends in health care coverage and service use for clients who received medical care from private providers. The RWHAP helps cover the cost of premiums and copays for these clients and provides medical and support services that help them stay engaged in care and virally suppressed. The RWHAP plays an important role in HIV care and treatment for clients with health care coverage. The growing number of people who receive a combination of services from RWHAP providers and private providers offers opportunities for greater care coordination through communication and data sharing between these settings.
- Open Access
- 6 November 2020
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 17 (11) , e1003128
Implementation science and the Health Resources and Services Administration’s Ryan White HIV/AIDS Program’s work towards ending the HIV epidemic in the United States
Demetrios Psihopaidas and co-authors discuss the implementation science framework of an HIV/AIDS program in the United States.
- 6 November 2020
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 17 (11) , e1003128
Open AccessImplementation science and the Health Resources and Services Administration’s Ryan White HIV/AIDS Program’s work towards ending the HIV epidemic in the United States
Demetrios Psihopaidas and co-authors discuss the implementation science framework of an HIV/AIDS program in the United States.
- Open Access
- 2 September 2020
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 222 (Supplement) , S477-S485
The Health Resources and Services Administration (HRSA) Ryan White HIV/AIDS Program’s Response to the Opioid Epidemic
Background: The United States is in the midst of an unprecedented opioid crisis with increasing injection drug use (IDU)-related human immunodeficiency virus (HIV) outbreaks, particularly in rural areas. The Health Resources and Services Administration (HRSA)’s Ryan White HIV/AIDS Program (RWHAP) is well positioned to integrate treatment for IDU-associated HIV infections with treatment for drug use disorders. These activities will be crucial for the “Ending the HIV Epidemic: A Plan for America” (EHE) initiative, in which 7 southern states were identified with rural HIV epidemics. Methods: The RWHAP Services Report data were used to assess the IDU population and substance use services utilization among RWHAP clients in 2017, nationally and in the 7 EHE-identified states. THe HRSA held a 1-day Technical Expert Panel (TEP) to explore how RWHAP can best respond to the growing opioid crisis. Results: During the TEP, 8 key themes emerged and 11 best practices were identified to address opioid use disorder (OUD) among people with HIV. In 2017, among RWHAP clients with reported age and transmission category, 6.7% (31 683) had HIV attributed to IDU; among IDU clients, 6.3% (1988) accessed substance use services. Conclusions: The TEP results and RWHAP data were used to develop implementation science projects that focus on addressing OUD and integrating behavioral health in primary care. These activities are critical to ending the HIV epidemic.
- 2 September 2020
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 222 (Supplement) , S477-S485
Open AccessThe Health Resources and Services Administration (HRSA) Ryan White HIV/AIDS Program’s Response to the Opioid Epidemic
Background: The United States is in the midst of an unprecedented opioid crisis with increasing injection drug use (IDU)-related human immunodeficiency virus (HIV) outbreaks, particularly in rural areas. The Health Resources and Services Administration (HRSA)’s Ryan White HIV/AIDS Program (RWHAP) is well positioned to integrate treatment for IDU-associated HIV infections with treatment for drug use disorders. These activities will be crucial for the “Ending the HIV Epidemic: A Plan for America” (EHE) initiative, in which 7 southern states were identified with rural HIV epidemics. Methods: The RWHAP Services Report data were used to assess the IDU population and substance use services utilization among RWHAP clients in 2017, nationally and in the 7 EHE-identified states. THe HRSA held a 1-day Technical Expert Panel (TEP) to explore how RWHAP can best respond to the growing opioid crisis. Results: During the TEP, 8 key themes emerged and 11 best practices were identified to address opioid use disorder (OUD) among people with HIV. In 2017, among RWHAP clients with reported age and transmission category, 6.7% (31 683) had HIV attributed to IDU; among IDU clients, 6.3% (1988) accessed substance use services. Conclusions: The TEP results and RWHAP data were used to develop implementation science projects that focus on addressing OUD and integrating behavioral health in primary care. These activities are critical to ending the HIV epidemic.
- Open Access
- 2 March 2020
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 17 (3) , e1003057
Addressing disparities in the health of persons with HIV attributable to unstable housing in the United States: The role of the Ryan White HIV/AIDS Program
Amy Griffin and co-authors discuss unstable housing and the response to HIV/AIDS in the United States.
- 2 March 2020
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 17 (3) , e1003057
Open AccessAddressing disparities in the health of persons with HIV attributable to unstable housing in the United States: The role of the Ryan White HIV/AIDS Program
Amy Griffin and co-authors discuss unstable housing and the response to HIV/AIDS in the United States.
- 1 May 2017
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 171 (5) , 421-422
Using Systems of Care and a Public Health Approach to Achieve Zero Perinatal HIV Transmissions
The United States has reduced new human immunodeficiency virus (HIV) infections and improved linkage to and retention in care for people living with HIV. New HIV infections have stabilized at approximately 45 000 per year from 130 000 new infections annually in the mid-1990s.1,2 In 2014, 74% of people were linked to care within a month of HIV diagnosis. In 2012, 55% of people living with HIV were retained in care.3 One of the most notable successes in battling the HIV epidemic in the United States to date has been the significant reduction in perinatal transmission, with elimination of mother-to-child transmission now a realistic goal. With the release in 1994 of the seminal AIDA Clinical Trials Group 076 study results demonstrating that a biomedical intervention of antiretroviral therapy could significantly reduce perinatal HIV transmission, the United States moved quickly to leverage the public health infrastructure and gain early successes.4,5 Illustrating the continued progress with preventing perinatal HIV transmission in the United States, in this issue of JAMA Pediatrics, Taylor et al6 report that the perinatal infection rate decreased from 5.37 per 100 000 live births in 2002 to 1.75 per 100000 live births in 2013.
- 1 May 2017
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 171 (5) , 421-422
Using Systems of Care and a Public Health Approach to Achieve Zero Perinatal HIV Transmissions
The United States has reduced new human immunodeficiency virus (HIV) infections and improved linkage to and retention in care for people living with HIV. New HIV infections have stabilized at approximately 45 000 per year from 130 000 new infections annually in the mid-1990s.1,2 In 2014, 74% of people were linked to care within a month of HIV diagnosis. In 2012, 55% of people living with HIV were retained in care.3 One of the most notable successes in battling the HIV epidemic in the United States to date has been the significant reduction in perinatal transmission, with elimination of mother-to-child transmission now a realistic goal. With the release in 1994 of the seminal AIDA Clinical Trials Group 076 study results demonstrating that a biomedical intervention of antiretroviral therapy could significantly reduce perinatal HIV transmission, the United States moved quickly to leverage the public health infrastructure and gain early successes.4,5 Illustrating the continued progress with preventing perinatal HIV transmission in the United States, in this issue of JAMA Pediatrics, Taylor et al6 report that the perinatal infection rate decreased from 5.37 per 100 000 live births in 2002 to 1.75 per 100000 live births in 2013.
- Open Access
- 1 March 2011
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 56 (Supplement) , S98-S104
Policy Implications of Integrating Buprenorphine/Naloxone Treatment and HIV Care
Researchers, practitioners, and policymakers have long recognized the potential benefits of providing integrated substance abuse and medical care services, particularly for special populations such as people living with HIV/AIDS. Buprenorphine, an office-based pharmacological treatment for opioid dependence, offers new opportunities for integrating drug treatment into HIV care settings. However, the historical separation between the drug treatment and medical care systems has resulted in a host of policy barriers. The Buprenorphine and HIV Care Evaluation and Support initiative, a multisite demonstration project to assess the feasibility and effectiveness of integrating buprenorphine/naloxone into HIV care settings, provided an opportunity to evaluate if and how policy barriers affect efforts to integrate HIV care and addiction treatment. We found that financing issues, workforce and training issues, and the operational consequences of some conceptual differences between HIV care and addiction treatment are barriers to the full integration of buprenorphine into HIV care. We recommend changes to financing and reimbursement policies, programs to strengthen the addiction treatment skills of physicians, and cross training between the fields of addiction, medicine, drug treatment, and HIV medicine. By addressing some of the policy barriers to integration, this promising new treatment can help the thousands of people living with HIV/AIDS who are also opioid dependent.
- 1 March 2011
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 56 (Supplement) , S98-S104
Open AccessPolicy Implications of Integrating Buprenorphine/Naloxone Treatment and HIV Care
Researchers, practitioners, and policymakers have long recognized the potential benefits of providing integrated substance abuse and medical care services, particularly for special populations such as people living with HIV/AIDS. Buprenorphine, an office-based pharmacological treatment for opioid dependence, offers new opportunities for integrating drug treatment into HIV care settings. However, the historical separation between the drug treatment and medical care systems has resulted in a host of policy barriers. The Buprenorphine and HIV Care Evaluation and Support initiative, a multisite demonstration project to assess the feasibility and effectiveness of integrating buprenorphine/naloxone into HIV care settings, provided an opportunity to evaluate if and how policy barriers affect efforts to integrate HIV care and addiction treatment. We found that financing issues, workforce and training issues, and the operational consequences of some conceptual differences between HIV care and addiction treatment are barriers to the full integration of buprenorphine into HIV care. We recommend changes to financing and reimbursement policies, programs to strengthen the addiction treatment skills of physicians, and cross training between the fields of addiction, medicine, drug treatment, and HIV medicine. By addressing some of the policy barriers to integration, this promising new treatment can help the thousands of people living with HIV/AIDS who are also opioid dependent.
- 1 March 2011
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 56 (Supplement) , S3-S6
A Model Federal Collaborative to Increase Patient Access to Buprenorphine Treatment in HIV Primary Care
A Health Resources and Services Administration-Substance Abuse and Mental Health Services Administration collaboration was established to improve health outcomes for opiate-dependent HIV-infected patients through promotion of integrated models of HIV primary care and substance abuse treatment. The collaboration comprised 10 demonstration sites coordinated by a technical assistance/evaluation center that worked to refine planned interventions, address state-of-the-art treatment and policy issues relating to the use of buprenorphine opioid abuse treatment in HIV primary care settings, conduct local and multisite evaluations, and disseminate program findings. This article describes the goals and objectives of the collaborative as well as the interagency interactions and steps taken to establish the collaborative.
- 1 March 2011
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 56 (Supplement) , S3-S6
A Model Federal Collaborative to Increase Patient Access to Buprenorphine Treatment in HIV Primary Care
A Health Resources and Services Administration-Substance Abuse and Mental Health Services Administration collaboration was established to improve health outcomes for opiate-dependent HIV-infected patients through promotion of integrated models of HIV primary care and substance abuse treatment. The collaboration comprised 10 demonstration sites coordinated by a technical assistance/evaluation center that worked to refine planned interventions, address state-of-the-art treatment and policy issues relating to the use of buprenorphine opioid abuse treatment in HIV primary care settings, conduct local and multisite evaluations, and disseminate program findings. This article describes the goals and objectives of the collaborative as well as the interagency interactions and steps taken to establish the collaborative.
- Open Access
- 15 December 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (Supplement) , S266-S274
Ensuring Access to Treatment for HIV Infection
The recent recommendations of the Centers for Disease Control and Prevention for opt-out testing are intended to address the evolving human immunodef
- 15 December 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (Supplement) , S266-S274
Open AccessEnsuring Access to Treatment for HIV Infection
The recent recommendations of the Centers for Disease Control and Prevention for opt-out testing are intended to address the evolving human immunodef
- Open Access
- 1 June 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 44 (11) , 1500-1502
Engaging HIV-Infected Patients in Care: Their Lives Depend on It
Potential conflicts of interest. L.W.C.: no conflicts.
- 1 June 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 44 (11) , 1500-1502
Open AccessEngaging HIV-Infected Patients in Care: Their Lives Depend on It
Potential conflicts of interest. L.W.C.: no conflicts.
- Open Access
- 1 August 1994
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 14 (8) , 4831-4838
Habituation of neurosecretory responses to extracellular ATP in PC12 cells
Neuronally differentiated PC12 cells have been used as a model for habituation. These cells secrete norepinephrine in response to extracellular ATP, as well as other stimulants, and the response is diminished with repetitive stimulation. This loss of neurosecretory responsiveness displays characteristics commonly associated with habituative learning. These include an increase in both the rate and the relative degree of response loss with either increasing stimulation frequency or decreasing stimulus intensity, and selective generalization of the decreased responsiveness to heterologous stimuli. In PC12 cells, the loss of neurosecretory responsiveness appears to be entirely caused by stimulation-dependent inactivation of the ATP-gated cation channel. Several unusual properties of this channel apparently allow its regulation to produce the behaviors associated with short- term habituation. Recovery of the ATP-gated channel requires several minutes, allowing habituation of responses to repetitive stimuli given at intervals of several minutes. Inactivation of the ATP-gated channel may be proportionately faster in response to lower ligand concentrations, allowing habituation to be more rapid in response to stimuli of weaker intensity.
- 1 August 1994
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 14 (8) , 4831-4838
Open AccessHabituation of neurosecretory responses to extracellular ATP in PC12 cells
Neuronally differentiated PC12 cells have been used as a model for habituation. These cells secrete norepinephrine in response to extracellular ATP, as well as other stimulants, and the response is diminished with repetitive stimulation. This loss of neurosecretory responsiveness displays characteristics commonly associated with habituative learning. These include an increase in both the rate and the relative degree of response loss with either increasing stimulation frequency or decreasing stimulus intensity, and selective generalization of the decreased responsiveness to heterologous stimuli. In PC12 cells, the loss of neurosecretory responsiveness appears to be entirely caused by stimulation-dependent inactivation of the ATP-gated cation channel. Several unusual properties of this channel apparently allow its regulation to produce the behaviors associated with short- term habituation. Recovery of the ATP-gated channel requires several minutes, allowing habituation of responses to repetitive stimuli given at intervals of several minutes. Inactivation of the ATP-gated channel may be proportionately faster in response to lower ligand concentrations, allowing habituation to be more rapid in response to stimuli of weaker intensity.